Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432089 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL2434335 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10KMT2ABTKHCRTR2 | |
| SCHEMBL3569177 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10KMT2ABTKHCRTR2 | |
| SCHEMBL2566481 | 0.75 | HSD17B10 (0.38) | SMN1; SMN2HSD17B10KMT2AHCRTR2MEN1 | |
| SCHEMBL3832136 | 0.75 | HSD17B10 (0.38) | SMN1; SMN2HSD17B10KMT2AHCRTR2MEN1 | |
| SCHEMBL2490765 | 0.73 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL3771067 | 0.73 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL29039261 | 0.73 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL2567398 | 0.72 | HSD17B10 (0.34) | SMN1; SMN2HSD17B10 | |
| SCHEMBL2432113 | 0.71 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10KMT2AHCRTR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | SMN1; SMN2 3702/4885HSD17B10 1607/4885KMT2A 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.